Myricx Bio, a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads based on N-myristoyltransferase inhibition (NMTi), announces the appointment of Dr Chris Martin as independent Chairman to its Board of Directors.
Dr Martin was instrumental in cofounding ADC Therapeutics in Januray 2012 and served as its CEO since inception until May 2022.
Under his leadership, ADC Therapeutics grew from a private biotech start-up to a New York Stock Exchange (NYSE) listed leader in the field of ADCs with products on the global market.
Chris previously cofounded and led two other biotech companies: Spirogen Ltd, an innovator of ADC payload technology, which was acquired by MedImmune, now part of AstraZeneca; and Sciona, Inc. a provider of personalised gene-based health and nutrition analyses.
Alongside his role as Chair of Myricx, he is also Chair of the Board of Tokamak Energy Ltd, and Tagworks Pharmaceuticals BV, and a Director on the Board of Osivax SAS.
Dr Martin succeeds Prof Roberto Solari, co,founder of Myricx who is stepping down from the board but will remain closely involved as a consultant to the company contributing his extensive drug discovery experience and knowledge.
A Fellow of the Institution of Chemical Engineers and a Sainsbury Management Fellow, Dr Martin holds a bachelor’s degree in chemical engineering from Aston University, a DPhil in Engineering Science from the University of Oxford, and an MBA from IMD Business School.
